← Back to Search
Hyaluronic Acid-based Nanocarriers For Intracellular Targeting: Interfacial Interactions With Proteins In Cancer.
K. Choi, G. Saravanakumar, J. Park, K. Park
Published 2012 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
The therapeutic efficacy of most drugs is greatly depends on their ability to cross the cellular barrier and reach their intracellular target sites. To transport the drugs effectively through the cellular membrane and to deliver them into the intracellular environment, several interesting smart carrier systems based on both synthetic or natural polymers have been designed and developed. In recent years, hyaluronic acid (HA) has emerged as a promising candidate for intracellular delivery of various therapeutic and imaging agents because of its innate ability to recognize specific cellular receptors that overexpressed on diseased cells. The aim of this review is to highlight the significance of HA in cancer, and to explore the recent advances of HA-based drug carriers towards cancer imaging and therapeutics.
This paper references
Sera of children with renal tumours contain low‐molecular‐mass hyaluronic acid
S. Kumar (1989)
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring.
K. Kim (2010)
G.V.T.V. Weerasooriya (1824)
Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation.
H. J. Terpe (1996)
Hydrotropic hyaluronic acid conjugates: synthesis
G. Saravanakumar (2010)
Identification of Hyaluronan-binding Domains of Aggrecan*
H. Watanabe (1997)
HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor.
V. Lokeshwar (2005)
Degradation of newly synthesized high molecular mass hyaluronan in the epidermal and dermal compartments of human skin in organ culture.
R. Tammi (1991)
Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: Comparison between invasive and non‐invasive areas
P. Bertrand (1992)
Mouse LYVE-1 Is an Endocytic Receptor for Hyaluronan in Lymphatic Endothelium*
R. Prevo (2001)
The dawning era of polymer therapeutics
R. Duncan (2003)
Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes.
H. Lee (2008)
Angiogenesis induced by degradation products of hyaluronic acid.
D. West (1985)
Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis.
Yu-Jeong Kim (2010)
Hyaluronan: from extracellular glue to pericellular cue
B. Toole (2004)
Self-assembled hyaluronic acid nanoparticles for active tumor targeting.
K. Choi (2010)
A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family
I. Stamenković (1989)
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Z. Qian (2002)
Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival.
P. Auvinen (2000)
TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity.
H. Wisniewski (1997)
A Smart Nanoprobe Based On Fluorescence-Quenching PEGylated Nanogels Containing Gold Nanoparticles for Monitoring the Response to Cancer Therapy
Motoi Oishi (2009)
Hyaluronan: its nature
J. R. Fraser (1997)
The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments.
V. Assmann (1999)
In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes.
K. K. Upadhyay (2010)
Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate
L. Setälä (1999)
Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins.
D. Parker (1995)
Characterization and identification of the hyaluronate binding site from membranes of SV-3T3 cells.
C. Underhill (1985)
Physical characteristics of hyaluronate binding to the surface of simian virus 40-transformed 3T3 cells.
C. Underhill (1980)
Hyaluronidase reduces human breast cancer xenografts in SCID mice
S. Shuster (2002)
Prevention of tumor metastasis formation by anti-variant CD44
S. Seiter (1993)
CD44 variant exon epitopes in primary breast cancer and length of survival
M. Kaufmann (1995)
Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function
Q. Yu (1997)
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.
T. Strobel (1997)
Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.
H. Pham (1997)
Hyaluronidases in cancer biology.
R. Stern (2008)
Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.
G. Jiang (2009)
HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion.
V. Lokeshwar (2005)
Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But
D. Coradini (2004)
Hyaluronan Oligosaccharides Inhibit Anchorage-independent Growth of Tumor Cells by Suppressing the Phosphoinositide 3-Kinase/Akt Cell Survival Pathway*
S. Ghatak (2002)
J. Lackie (2013)
P. Weigel (1997)
Targeting of drugs
G. Gregoriadis (1977)
Hyaluronan: its nature, distribution, functions and turnover
J. E. Fraser (1997)
CD44-dependent Intracellular and Extracellular Catabolism of Hyaluronic Acid by Hyaluronidase-1 and -2*
Hosami Harada (2007)
Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells.
V. Lokeshwar (2000)
O. Farokhzad (2004)
Nanocarriers as an emerging platform for cancer therapy
S. Wise (2007)
Distinct effects of two CD44 isoforms on tumor growth in vivo
M. Sy (1991)
Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines.
N. Junker (2003)
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
E. Auzenne (2007)
The over-expression of , and CD44 is implicated in the invasiveness of breast cancer
Lishanthi Udabage (2005)
Preparation and characterization of HA–PEG–PCL intelligent core–corona nanoparticles for delivery of doxorubicin
A. Yadav (2008)
Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis.
K. Chao (2007)
Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models
D. Peer (2004)
Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis.
W. Knudson (1984)
Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells.
N. Liu (2001)
Human breast‐cancer metastasis formation in a nude‐mouse model: Studies of hyaluronidase, hyaluronan and hyaluronan‐binding sites in metastatic cells
R. Victor (1999)
Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition.
H. Mok (2007)
Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe.
S. Lee (2011)
The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity.
C. Underhill (1987)
A human lymphocyte homing receptor, the Hermes antigen, is related to cartilage proteoglycan core and link proteins
L. Goldstein (1989)
Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1.
V. Lokeshwar (1999)
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
A. Lukyanov (2004)
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
J. Kim (2008)
Synergistically Integrated Nanoparticles as Multimodal Probes for Nanobiotechnology
Jinwoo Cheon (2009)
Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment
Woochan Hyung (2008)
A cell surface integral membrane glycoprotein of 85,000 mol wt (gp85) associated with triton X-100-insoluble cell skeleton
G. Tarone (1984)
V. Torchilin (2006)
Active targeting schemes for nanoparticle systems in cancer therapeutics.
J. D. Byrne (2008)
Lectin-mediated drug targeting: history and applications.
C. Bies (2004)
Identification of the Hyaluronan Receptor for Endocytosis (HARE)*
Bin Zhou (2000)
Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients.
A. Calabro (2002)
Folate-mediated delivery of macromolecular anticancer therapeutic agents.
Y. Lu (2002)
Hyaluronate and invasiveness of the rabbit V2 carcinoma.
B. Toole (1979)
Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B‐cell non‐Hodgkin lymphoma: Relationship with tumor aggressiveness
P. Bertrand (2005)
Hyaluronidase is more elevated in human brain metastases than in primary brain tumours.
B. Delpech (2002)
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention.
S. Sahoo (2005)
Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
R. E. Eliaz (2001)
Selective Expression and Functional Characteristics of Three Mammalian Hyaluronan Synthases in Oncogenic Malignant Transformation*
N. Itano (2004)
Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M.
H. Koyama (2007)
Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
A. Yadav (2007)
Drug targeting to the colon with lectins and neoglycoconjugates.
T. Minko (2004)
Biology and Medical Applications of Hyaluronan and its Derivatives
T. Laurent (1998)
LYVE-1a new homologue of the CD44 glycoprotein
S. Banerji (1999)
Splice variants of CD44 in human cervical cancer stage IB to IIB.
C. Kainz (1995)
Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity.
H. Lee (2008)
Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.
V. J. Wielenga (1993)
Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis.
R. Lee (1994)
CD44 in Cancer
D. Naor (2002)
HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer.
A. Rosato (2006)
Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro.
R. Montesano (1996)
Seguin Hen (1824)
Correlated metabolism of proteoglycans and hyaluronic acid in bovine cartilage organ cultures.
T. Morales (1988)
The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer.
Lishanthi Udabage (2005)
Structure of human hyaluronidase-1
K. L Chao (2007)
Expression of HYAL2 mRNA
P. Bertrand (2005)
Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation.
G. Kaya (1997)
Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin.
H. Lee (2009)
Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells.
Jeanine A Ward (2003)
P. Wakeley (2013)
Cancer nanotechnology: opportunities and challenges
M. Ferrari (2005)
Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer.
K. Ropponen (1998)
Lecticans: organizers of the brain extracellular matrix
Y. Yamaguchi (2000)
Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors
A. Jacobson (2002)
CD44 is the principal cell surface receptor for hyaluronate
A. Aruffo (1990)
Correction. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
C. Hardwick (1992)
Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer*
V. Lokeshwar (2001)
Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand.
S. J. Na (2008)
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan
S. Banerji (1999)
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
H. Maeda (2001)
Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan: evidence for CD44 and CD54 (intercellular adhesion molecule 1) invovement.
G. Lisignoli (2001)
Nanomedicine: developing smarter therapeutic and diagnostic modalities.
O. Farokhzad (2006)
Solution Structure of the Link Module: A Hyaluronan-Binding Domain Involved in Extracellular Matrix Stability and Cell Migration
D. Kohda (1996)
Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate.
Y. Luo (1999)
Expression of PH-20 in normal and neoplastic breast tissue.
D. Beech (2002)
Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
T. Hirata (1998)
Preparation and characterization of hyaluronic acid-based hydrogel nanoparticles
K. Choi (2008)
The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes.
K. K. Upadhyay (2010)
Develop - ment and characterization of hyaluronic acid - anchored PLGA nanoparticulate carriers of doxorubicin , nanomedicine : nanotechnology
S. Lee (2007)
Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
S. Hautmann (2004)
The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate‐bearing cells.
I. Stamenković (1991)
Lymphatic endothelium‐specific hyaluronan receptor LYVE‐1 is expressed by stabilin‐1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis
K. Schledzewski (2006)
Expression of cd44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential
E. Manten-Horst (1995)
HA receptors: Regulators of signalling to the cytoskeleton
J. Entwistle (1996)
Hyaluronidase and CD44 hyaluronan receptor expression in squamous cell laryngeal carcinoma.
T. A. Christopoulos (2006)
Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis.
Q. Hua (1993)
Polymeric nanomedicine for cancer therapy
J. Park (2008)
Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44.
M. Birch (1991)
Inhibition of tumor growth in vivo by hyaluronan oligomers
C. Zeng (1998)
Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors
E. Franzmann (2003)
Soluble CD44 splice variants in metastasizing human breast cancer
S. Martin (1997)
Identity of Hyaluronidase and Spreading Factor
E. Chain (1940)
Isolation of a Crystalline Disaccharide, Hyalobiuronic Acid, from Hyaluronic Acid
M. Rapport (1951)
Hyaluronan and Homeostasis: A Balancing Act*
M. Tammi (2002)
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
U. Guenthert (1991)
Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
V. Lokeshwar (2000)
CD44 in inflammation and metastasis
J. Lesley (2004)
Prognostic value of CD44 splice variant expression in ovarian cancer.
M. Uhl-Steidl (1995)
CD44 Interaction with Na+-H+ Exchanger (NHE1) Creates Acidic Microenvironments Leading to Hyaluronidase-2 and Cathepsin B Activation and Breast Tumor Cell Invasion*
L. Bourguignon (2004)
Hydrotropic Solubilization of Paclitaxel: Analysis of Chemical Structures for Hydrotropic Property
J. Lee (2004)
Drug delivery and targeting.
R. Langer (1998)
Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent.
M. Zahalka (1995)
Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts.
T. Asplund (1993)
A human lymphocyte homing receptor
L. A. Goldstein (1989)
Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival.
K. Endo (2000)
The specific interaction of hyaluronic acid with cartillage proteoglycans.
T. Hardingham (1972)
Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat tests
V. Lokeshwar (2002)
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels.
H. Lee (2007)
Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice.
M. Simpson (2002)
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
P. Sapra (2002)
Tumor targeting using anti-her2 immunoliposomes.
J. Park (2001)
Targeting Hyaluronan Interactions in Malignant Gliomas and Their Drug-Resistant Multipotent Progenitors
A. G. Gilg (2008)
CD44 cell adhesion molecules.
S. Goodison (1999)
Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution
K. Choi (2009)
J. Lackie (2013)
E. Dürr (2012)
Hydrotropic hyaluronic acid conjugates: Synthesis, characterization, and implications as a carrier of paclitaxel.
G. Saravanakumar (2010)
De-novo expression of CD44 and survival in gastric cancer
B. Mayer (1993)
Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti‐proliferative activity on a breast‐cancer cell line
D. Coradini (1999)
Bioinspired Surface Immobilization of Hyaluronic Acid on Monodisperse Magnetite Nanocrystals for Targeted Cancer Imaging.
Yu-han Lee (2008)
Hyaluronan oligosaccharides induce tube formation of a brain endothelial cell line in vitro.
Mehdi Rahmanian (1997)
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
O. Farokhzad (2006)
Hyaluronidases: their genomics, structures, and mechanisms of action.
Robert H. Stern (2006)
Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice.
M. Simpson (2006)
Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes
R. E. Eliaz (2004)
Protein expression of CD 44 ( standard and variant isoforms ) in hepatocellular carcinoma : relationships with tumor grade , clinicopatho - logic parameters , p 53 expression , and patient survival
P. Kohlberger (2000)
THE POLYSACCHARIDE OF THE VITREOUS HUMOR
K. Meyer (1934)
Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity.
R. Kosaki (1999)
Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression.
V. Lokeshwar (1996)
C. Lemarchand (2004)
PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo.
K. Choi (2011)
Simple primary structure, complex turnover regulation and multiple roles of hyaluronan.
N. Itano (2008)
Hyaluronidase-Sensitive SPIONs for MR/Optical Dual Imaging Nanoprobes
The Hyaluronan Receptor RHAMM Regulates Extracellular-regulated Kinase*
S. Zhang (1998)
Hyaluronan-binding Proteins: Tying Up the Giant*
A. J. Day (2002)
Increased hyaluronidase levels in breast tumor metastases
P. Bertrand (1997)
Expression of hyaluronidase by tumor cells induces angiogenesis in vivo.
D. Liu (1996)
CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.
R. Stauder (1995)
This paper is referenced by
Micellar carriers for the delivery of multiple therapeutic agents.
Rajesh Thipparaboina (2015)
Protamine-based nanoparticles as new antigen delivery systems.
J. V. González-Aramundiz (2015)
Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy.
H. Han (2015)
Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma.
Dalia M Kabary (2018)
Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid
Jing Yao (2014)
Characterization of the Tumor Microenvironment and Tumor–Stroma Interaction by Non-invasive Preclinical Imaging
N. Ramamonjisoa (2017)
Hyaluronic acid-coated nanoparticles as biofunctional pharmaceutical carriers
Abdulaziz Almalik (2013)
Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
Yumin Oh (2015)
Tumor‐Targeting Photothermal Heating‐Responsive Nanoplatform Based on Reduced Graphene Oxide/Mesoporous Silica/Hyaluronic Acid Nanocomposite for Enhanced Photodynamic Therapy
Wenjing Jiang (2017)
A novel crosslinked hyaluronic acid nanogel for drug delivery.
S. Pedrosa (2014)
Preparation and characterization of a novel polysialic acid-hyaluronan graft copolymer potential as dermal filler.
Jianrong Wu (2017)
Particle engineering for the production of respirable dry powder formulations
F. Martinelli (2016)
Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy
N. V. Rao (2018)
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Edgar Pérez-Herrero (2015)
β-Ga2O3:Cr(3+) nanoparticle: A new platform with near infrared photoluminescence for drug targeting delivery and bio-imaging simultaneously.
Xinshi Wang (2015)
Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application
S. P. Egusquiaguirre (2016)
Coumarin-containing thermoresponsive hyaluronic acid-based nanogels as delivery systems for anticancer chemotherapy.
T. F. Stefanello (2017)
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery
S. Misra (2015)
Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors
Lydia Ramzy (2017)
Quantitative analysis of ligand effects on bioefficacy of nanoemulsion encapsulating depigmenting active.
Nicolas Atrux-Tallau (2014)
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer.
K. Choi (2012)
Induction of Cancer Cell Death by Hyaluronic Acid-Mediated Uptake of Cytochrome C
C. Figueroa (2015)
Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
H. Han (2015)
Hyaluronan nanocapsules as a new vehicle for intracellular drug delivery.
F. Oyarzun-Ampuero (2013)
Endogenous inspired biomineral‐installed hyaluronan nanoparticles as pH‐responsive carrier of methotrexate for rheumatoid arthritis
M. M. Alam (2017)
Hyaluronic acid and its derivatives in drug delivery and imaging: Recent advances and challenges.
G. Tripodo (2015)
Mechanisms of cellular uptake with hyaluronic acid—octadecylamine micelles as drug delivery nanocarriers
Lipeng Qiu (2016)
Chitosan/poly(ethylene glycol)/hyaluronic acid biocompatible patches obtained by electrospraying.
Esra Cansever Mutlu (2018)
Nanotechnology: The Future for Cancer Treatment
Yogita Patil-Sen (2019)
Stimuli-Responsive Polymeric Nanocarriers as Promising Drug and Gene Delivery Systems
G. Saravanakumar (2014)
Tumor-selective lipopolyplex encapsulated small active RNA hampers colorectal cancer growth in vitro and in orthotopic murine.
L. Wang (2017)
A facile, one-step nanocarbon functionalization for biomedical applications.
M. Swierczewska (2012)See more